| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| J C Morris, P A Cyrus, J Orazem, J Mas, F Bieber, B B Ruzicka, B Gulansk. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease. Neurology. vol 50. issue 5. 1998-06-08. PMID:9595967. |
to evaluate the efficacy and safety of metrifonate, an acetylcholinesterase inhibitor, in patients clinically diagnosed with probable alzheimer's disease (ad) of mild to moderate severity. |
1998-06-08 |
2023-08-12 |
Not clear |
| S L Rogers, R S Doody, R C Mohs, L T Friedhof. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group. Archives of internal medicine. vol 158. issue 9. 1998-06-04. PMID:9588436. |
donepezil hydrochloride (aricept) is a selective acetylcholinesterase inhibitor developed for the treatment of alzheimer disease. |
1998-06-04 |
2023-08-12 |
Not clear |
| K Otoguro, F Kuno, S Omur. Arisugacins, selective acetylcholinesterase inhibitors of microbial origin. Pharmacology & therapeutics. vol 76. issue 1-3. 1998-05-21. PMID:9535168. |
synthetic inhibitors of acetylcholinesterase (ache) recently have attracted particular attention for treatment of alzheimer's disease. |
1998-05-21 |
2023-08-12 |
Not clear |
| R E Becker, J A Colliver, S J Markwell, P L Moriearty, L K Unni, S Vicar. Effects of metrifonate on cognitive decline in Alzheimer disease: a double-blind, placebo-controlled, 6-month study. Alzheimer disease and associated disorders. vol 12. issue 1. 1998-05-14. PMID:9539412. |
the alzheimer disease assessment scale cognitive subscale score of the metrifonate group treated to a 50-70% inhibition of red blood cell acetylcholinesterase activity differed significantly from the placebo group score by 1.8 points (p < 0.03) due to a deterioration in cognitive performance in the placebo group (p < 0.01). |
1998-05-14 |
2023-08-12 |
Not clear |
| A Alvarez, R Alarcón, C Opazo, E O Campos, F J Muñoz, F H Calderón, F Dajas, M K Gentry, B P Doctor, F G De Mello, N C Inestros. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 18. issue 9. 1998-05-05. PMID:9547230. |
stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of alzheimer's fibrils. |
1998-05-05 |
2023-08-12 |
Not clear |
| A Alvarez, R Alarcón, C Opazo, E O Campos, F J Muñoz, F H Calderón, F Dajas, M K Gentry, B P Doctor, F G De Mello, N C Inestros. Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils. The Journal of neuroscience : the official journal of the Society for Neuroscience. vol 18. issue 9. 1998-05-05. PMID:9547230. |
brain acetylcholinesterase (ache) forms stable complexes with amyloid-beta peptide (abeta) during its assembly into filaments, in agreement with its colocalization with the abeta deposits of alzheimer's brain. |
1998-05-05 |
2023-08-12 |
Not clear |
| E O Campos, A Alvarez, N C Inestros. Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides. Neurochemical research. vol 23. issue 2. 1998-04-03. PMID:9475506. |
it has been suggested that acetylcholinesterase (ache) has both a putative proteolytic activity against the amyloid precursor protein (app), and a capacity to accelerate the assembly of amyloid-beta-peptide (abeta) into alzheimer's fibrils. |
1998-04-03 |
2023-08-12 |
cattle |
| E Y Shintani, K M Uchid. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 54. issue 24. 1998-02-13. PMID:9428950. |
donepezil is a synthetic noncovalent reversible inhibitor of acetylcholinesterase (ache) for the treatment of mild to moderate dementia associated with alzheimer's disease. |
1998-02-13 |
2023-08-12 |
Not clear |
| E Perola, L Cellai, D Lamba, L Filocamo, M Brufan. Long chain analogs of physostigmine as potential drugs for Alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. Biochimica et biophysica acta. vol 1343. issue 1. 1998-01-30. PMID:9428657. |
long chain analogs of physostigmine as potential drugs for alzheimer's disease: new insights into the mechanism of action in the inhibition of acetylcholinesterase. |
1998-01-30 |
2023-08-12 |
Not clear |
| W Sihver, P Günther, R Schliebs, V Big. Repeated administration of tacrine to normal rats: effects on cholinergic, glutamatergic, and GABAergic receptor subtypes in rat brain using receptor autoradiography. Neurochemistry international. vol 31. issue 5. 1997-12-22. PMID:9364455. |
tacrine, a potent acetylcholinesterase inhibitor, has been reported to improve cognitive function in patients with alzheimer's disease. |
1997-12-22 |
2023-08-12 |
rat |
| R Beeri, N Le Novère, R Mervis, T Huberman, E Grauer, J P Changeux, H Sore. Enhanced hemicholinium binding and attenuated dendrite branching in cognitively impaired acetylcholinesterase-transgenic mice. Journal of neurochemistry. vol 69. issue 6. 1997-12-12. PMID:9375677. |
in a search for behavioral, neuroanatomical, and metabolic characteristics of alzheimer's disease that may result from cholinergic malfunction, we used transgenic mice overexpressing acetylcholinesterase (ache) mrna and active enzyme in brain neurons. |
1997-12-12 |
2023-08-12 |
mouse |
| M T McKenna, G R Proctor, L C Young, A L Harve. Novel tacrine analogues for potential use against Alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors. Journal of medicinal chemistry. vol 40. issue 22. 1997-12-11. PMID:9357518. |
novel tacrine analogues for potential use against alzheimer's disease: potent and selective acetylcholinesterase inhibitors and 5-ht uptake inhibitors. |
1997-12-11 |
2023-08-12 |
Not clear |
| P Kása, Z Rakonczay, K Guly. The cholinergic system in Alzheimer's disease. Progress in neurobiology. vol 52. issue 6. 1997-11-05. PMID:9316159. |
although the disease is characterized by multiple deficits of neurotransmitters in the brain, this overview emphasizes the structural and neurochemical localization of the elements of the acetylcholine system (choline acetyltransferase, acetylcholinesterase, and muscarinic and nicotinic acetylcholine receptors) in the non-demented brain and in alzheimer's disease brain samples. |
1997-11-05 |
2023-08-12 |
Not clear |
| A Alvarez, C Opazo, R Alarcón, J Garrido, N C Inestros. Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils. Journal of molecular biology. vol 272. issue 3. 1997-10-28. PMID:9325095. |
acetylcholinesterase (ache), an enzyme involved in the hydrolysis of the neurotransmitter acetylcholine, consistently colocalizes with the amyloid deposits characteristic of alzheimer's disease and may contribute to the generation of amyloid proteins and/or physically affect fibril assembly. |
1997-10-28 |
2023-08-12 |
Not clear |
| J Sáez-Valero, G Sberna, C A McLean, C L Masters, D H Smal. Glycosylation of acetylcholinesterase as diagnostic marker for Alzheimer's disease. Lancet (London, England). vol 350. issue 9082. 1997-10-23. PMID:9314873. |
glycosylation of acetylcholinesterase as diagnostic marker for alzheimer's disease. |
1997-10-23 |
2023-08-12 |
Not clear |
| R F Stachlewitz, G E Arteel, J A Raleigh, H D Connor, R P Mason, R G Thurma. Development and characterization of a new model of tacrine-induced hepatotoxicity: role of the sympathetic nervous system and hypoxia-reoxygenation. The Journal of pharmacology and experimental therapeutics. vol 282. issue 3. 1997-10-17. PMID:9316876. |
tacrine is an acetylcholinesterase inhibitor approved for the treatment of alzheimer's disease. |
1997-10-17 |
2023-08-12 |
rat |
| M Recanatini, A Cavalli, C Hansc. A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease. Chemico-biological interactions. vol 105. issue 3. 1997-10-02. PMID:9291997. |
a comparative qsar analysis of acetylcholinesterase inhibitors currently studied for the treatment of alzheimer's disease. |
1997-10-02 |
2023-08-12 |
Not clear |
| M Recanatini, A Cavalli, C Hansc. A comparative QSAR analysis of acetylcholinesterase inhibitors currently studied for the treatment of Alzheimer's disease. Chemico-biological interactions. vol 105. issue 3. 1997-10-02. PMID:9291997. |
considering the relevance of acetylcholinesterase inhibitors as potential agents for the treatment of the alzheimer's disease, we have undertaken a comparative qsar analysis aimed at individuating the physico-chemical properties governing the inhibitory activity of such compounds. |
1997-10-02 |
2023-08-12 |
Not clear |
| G Sberna, J Sáez-Valero, K Beyreuther, C L Masters, D H Smal. The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. Journal of neurochemistry. vol 69. issue 3. 1997-09-25. PMID:9282941. |
the amyloid beta-protein of alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma p19 cells. |
1997-09-25 |
2023-08-12 |
Not clear |
| G Sberna, J Sáez-Valero, K Beyreuther, C L Masters, D H Smal. The amyloid beta-protein of Alzheimer's disease increases acetylcholinesterase expression by increasing intracellular calcium in embryonal carcinoma P19 cells. Journal of neurochemistry. vol 69. issue 3. 1997-09-25. PMID:9282941. |
one of the characteristic changes that occurs in alzheimer's disease is the loss of acetylcholinesterase (ache) from both cholinergic and noncholinergic neurons of the brain. |
1997-09-25 |
2023-08-12 |
Not clear |